A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer

Ki vehet részt

• Part A
• Pathologically confirmed estrogen and/or progesterone receptor (ER/PR) positive and HER2 negative locoregionally recurrent or metastatic breast cancer
• At least one target or non-target lesion per RECIST v1.1 criteria
• Male or non-pregnant, non-lactating female subjects age ≥18 years; Part B
• Pathologically confirmed estrogen and/or progesterone receptor (ER/PR) positive and HER2 negative locoregionally recurrent or metastatic breast cancer
• Refractory to endocrine therapy. Note: there is no limit on prior number of lines of endocrine therapy or prior treatments with CDK4/6, AKT, PI3K and/or mTOR inhibitors
• Received or declined at least one line of chemotherapy or antibody drug conjugate in the locoregionally recurrent or metastatic setting
• Progressive disease or intolerance to last treatment
• At least one target lesion per RECIST v1.1 criteria
• Male or non-pregnant, non-lactating female subjects age ≥18 years
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
• Life expectancy of at least six months
• Adequate bone marrow reserve, hepatic function and renal function

Ki nem vehet részt

• Study participant has not recovered from clinically significant adverse event(s) resulting from most recent anticancer therapy/intervention
• Radiotherapy for breast cancer ≤ 28 days prior
• Received a radionuclide within a period of less than 10 physical half-lives of the administered radionuclide prior to dosing with 68Ga-R11228
• Study participant has not recovered from clinically significant adverse event(s) resulting from most recent anticancer therapy/intervention
• Treatment with anticancer therapy or with an investigational drug or device within 21 days or 5 half-lives of the agent (whichever is shorter)
• Prior systemic radionuclide therapeutic treatment
• Received a radionuclide within a period of less than 10 physical half-lives of the administered radionuclide prior to dosing with 68Ga-R11228
• Any unresolved NCI-CTCAE Version 5.0 Grade 2 or higher toxicity (except alopecia and Grade 2 platinum-therapy related neuropathy) from previous breast cancer treatment and/or from medical/surgical procedures or interventions
• Known central nervous system (CNS) disease, except for those subjects with treated brain metastasis who are stable for at least 1 month, having no evidence of progression or hemorrhage after treatment and no ongoing requirement for corticosteroids, as ascertained by clinical examination and brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT]) during the screening period
• Any condition that precludes the proper performance of imaging procedures required in this study; Part B
• Known central nervous system (CNS) disease, except for those subjects with treated brain metastasis who are stable for at least 1 month, having no evidence of progression or hemorrhage after treatment and no ongoing requirement for corticosteroids, as ascertained by clinical examination and brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT]) during the screening period
• Radiotherapy for breast cancer ≤ 28 days
• Any condition that precludes the proper performance of imaging procedures required in this study
• Part A